The involvement of HER2 and p53 status in the regulation of telomerase in irradiated breast cancer cells

International Journal of Oncology

Volumn 35, Issue 5, 2009, Pages 1141-1149

  Papanikolaou, Vassilis ^a,b   Iliopoulos, Dimitrios ^c   Dimou, Ioannis ^d   Dubos, Stephanie ^b   Tsougos, Ioannis ^a   Theodorou, Kyriaki ^a   Kitsiou Tzeli, Sofia ^e   Tsezou, Aspasia ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^c OHIO STATE UNIVERSITY   (United States)

^d TECHNICAL UNIVERSITY OF CRETE   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; HER2; Ionizing radiation; P53; Telomerase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HISTONE; MESSENGER RNA; MYC PROTEIN; PROTEIN P53; TELOMERASE;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INTERACTION; HUMAN; HUMAN CELL; IONIZING RADIATION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RADIATION TOLERANCE; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 70449592217     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000430     Document Type: Article

References (32)

1. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ and Tong T: The lifetime risk of developing breast cancer. J Natl Cancer Inst 85: 892-897, 1993. (Pubitemid 23157129)
2. Gee JM and Nicholson RI: Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 5: 126-129, 2003. (Pubitemid 36519404)
3. Lichter AS and Lawrence TS: Recent advances in radiation oncology. N Engl J Med 332: 371-379, 1995.
4. Canman CE, Gilmer TM, Coutts S and Kastan M: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-611, 1995.
5. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
6. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997. (Pubitemid 27239490)
7. Pandita TK and Roti Roti JL: Role of telomerase in radiocurability. Oncol Rep 10: 263-270, 2003.
8. Asker C, Wiman KG and Selivanova G: p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 265: 1-6, 1999.
9. Xu D, Wang Q, Gruber A, Björkholm M, Chen Z, Zaid A, Selivanova G, Peterson C, Wiman KG and Pisa P: Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123-5133, 2000. (Pubitemid 30835049)
10. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB and Bacchetti S: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921-1929, 1992.
11. Greider CW and Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337: 331-337, 1989.
12. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ and Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315: 1850-1853, 2007.
13. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997. (Pubitemid 27357969)
14. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959, 1997. (Pubitemid 27366681)
15. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352, 1998. (Pubitemid 28063364)
16. Sawant SG, Gregoire V, Dhar S, Umbricht CB, Cvilic S, Sukumar S and Pandita TK: Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB J 13: 1047-1054, 1999. (Pubitemid 29249730)
17. Kyo S and Inoue M: Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 21: 688-697, 2002.
18. Goueli BS and Janknecht R: Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25-35, 2004.
19. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
20. Satra M, Tsougos I, Papanikolaou V, Theodorou K, Kappas C and Tsezou A: Correlation between radiation-induced telomerase activity and human telomerase reverse transcriptase mRNA expression in HeLa cells. Int J Radiat Biol 82: 401-409, 2006. (Pubitemid 44086993)
21. Tsezou A, Oikonomou P, Kollia P, Mademtzis I, Kostopoulou E, Messinis I and Vamvakopoulos N: The role of human telomerase catalytic subunit mRNA expression in cervical dysplasias. Exp Biol Med 230: 263-270, 2005. (Pubitemid 40478251)
22. Liang K, Lu Y, Jin W, Ang KK, Milas L and Fan Z: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2: 1113-1120, 2003.
23. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
24. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61: 1-13, 2001. (Pubitemid 33033419)
25. Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, Nakamura M and Tanaka M: Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cncer cells. Clin Cancer Res 5: 2140-2147, 1999. (Pubitemid 29399270)
26. Shats I, Myliavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D and Rotter V: p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 279: 50976-50985, 2004. (Pubitemid 40017838)
27. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ: Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14: 981-993, 2000. (Pubitemid 30253006)
28. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and Vogelstein B: Definition of a consensus binding site for p53. Nat Genet 1: 45-49, 1992.
29. Cosgrave N, Hill AD and Young LS: Growth factor-dependent regulation of survivin by c-myc in human breast cancer. J Mol Endocrinol 37: 377-390, 2006. (Pubitemid 46085164)
30. Fujiki T, Miura T, Maura M, Shiraishi H, Nishimura S, Imada Y, Uehara N, Tashiro K, Shirahata S and Katakura Y: TAK1 represses transcription of the human telomerase reverse transcriptase gene. Oncogene 26: 5258-5266, 2007. (Pubitemid 47237626)
31. Xu D, Popov N, Hou M, Wang O, Björkholm M, Gruber A, Menkel AR and Henriksson M: Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 98: 3826-3831, 2001. (Pubitemid 32249856)
32. Cole MD and McMahon SB: The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18: 2916-2924, 1999. (Pubitemid 29276532)